Aprea Therapeutics
APRE
64 hedge funds and large institutions have $405M invested in Aprea Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 8 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
43% more capital inflows, than outflows
Capital inflows: $26.2M | Capital outflows: $18.4M
1.2% more ownership
Funds ownership: 78.24% → 79.44% (+1.2%)
0% more funds holding
Funds holding: 64 → 64 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
+$5.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.55M |
| 3 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.88M |
| 4 |
Palo Alto Investors
Palo Alto,
California
|
+$2.03M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.57M |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$6.14M |
| 3 |
Janus Henderson Group
London,
|
-$2.61M |
| 4 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$560K |
| 5 |
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
|
-$460K |
APRE Hedge Fund Activity: Q3 2020 in Review
64 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q3 2020, worth a combined $405M — down 37% from $639M a quarter earlier.
Fund positioning in APRE was balanced in Q3 2020: 8 funds opened new positions, 8 closed out, 23 added to existing stakes and 16 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $5.8M. The largest seller was Citadel Advisors, cutting an estimated $6.57M.
- 64 institutional investors held Aprea Therapeutics (APRE) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $405M of Aprea Therapeutics stock for Q3 2020, down 37% quarter-over-quarter.
- 8 funds opened new Aprea Therapeutics positions in Q3 2020 and 8 closed out, a net change of 0 holders.
- The largest Aprea Therapeutics buyer in Q3 2020 was Consonance Capital Management, an estimated $5.8M added.
- The largest Aprea Therapeutics seller in Q3 2020 was Citadel Advisors, an estimated $6.57M sold.
Based on aggregated 13F filings for Q3 2020.